Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.36) per share. This is a 50 percent decrease over losses of $(0.24) per share from the same period last year.
Related Posts
DOGE Proponents Express Hope And Concerns Related To Dogecoin-Ethereum Bridges
Dogecoin (CRYPTO: DOGE) co-founder Billy Markus and popular DOGE news account Mishaboar shared their opinions on independently developed bridges between DOGE and Ethereum (CRYPTO:
Morgan Stanley Maintains Overweight on SBA Communications, Raises Price Target to $405
Morgan Stanley analyst Simon Flannery maintains SBA Communications (NASDAQ:SBAC) with a Overweight and raises the price target from $337 to $405.
ORIC Pharmaceuticals Presents Initial Clinical Data From Phase 1b Trial Of ORIC-101 In Combination With Enzalutamide And Preclinical Data On ORIC-114 at AACR-NCI-EORTC
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced multiple presentations, including initial